Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedThe site footer revision identifier changed from v3.7.2 to v3.8.0 while the study page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” terminology was added. The site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check23 days agoChange DetectedThe footer's displayed site revision changes from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study details, indicating that the study record is temporarily inaccessible. Users cannot view the study information on this URL until access is restored.SummaryDifference18%

- Check50 days agoChange DetectedThe page now shows revision tag v3.7.0, replacing the previous v3.6.6. This indicates an update to the page version without changes to the study details shown.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6 on the page, indicating a minor update to the page's revision history. This update does not alter the study details or user-facing content.SummaryDifference0.1%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.